Compare Stocks: BOLT, BRNS, JSPR, and QNTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$3.66 +14.4%	$3.94	$3.13 ▼ $7.20	$7.06M	1.18	23,771 shs	65,147 shs
BRNS Barinthus Biotherapeutics	$0.62 +1.5%	$0.63	$0.51 ▼ $1.83	$25.40M	-0.39	33,554 shs	11,679 shs
JSPR Jasper Therapeutics	$0.72 +3.6%	$0.62	$0.32 ▼ $3.05	$20.05M	3.02	770,719 shs	780,838 shs
QNTM Quantum Biopharma	$3.44	$3.38	$2.07 ▼ $21.00	$22.01M	0.45	292,019 shs	137,564 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	+9.25%	-3.94%	-26.06%	-25.00%
BRNS Barinthus Biotherapeutics	0.00%	+5.19%	+3.62%	-10.29%	-45.46%
JSPR Jasper Therapeutics	0.00%	-9.38%	-1.80%	-20.71%	-74.88%
QNTM Quantum Biopharma	0.00%	-9.47%	+21.13%	-62.77%	-81.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$3.66 +14.4%	$3.94	$3.13 ▼ $7.20	$7.06M	1.18	23,771 shs	65,147 shs
BRNS Barinthus Biotherapeutics	$0.62 +1.5%	$0.63	$0.51 ▼ $1.83	$25.40M	-0.39	33,554 shs	11,679 shs
JSPR Jasper Therapeutics	$0.72 +3.6%	$0.62	$0.32 ▼ $3.05	$20.05M	3.02	770,719 shs	780,838 shs
QNTM Quantum Biopharma	$3.44	$3.38	$2.07 ▼ $21.00	$22.01M	0.45	292,019 shs	137,564 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	+9.25%	-3.94%	-26.06%	-25.00%
BRNS Barinthus Biotherapeutics	0.00%	+5.19%	+3.62%	-10.29%	-45.46%
JSPR Jasper Therapeutics	0.00%	-9.38%	-1.80%	-20.71%	-74.88%
QNTM Quantum Biopharma	0.00%	-9.47%	+21.13%	-62.77%	-81.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.25	Hold	$14.50	296.17% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	543.40% Upside
JSPR Jasper Therapeutics	2.50	Moderate Buy	$8.17	1,040.60% Upside
QNTM Quantum Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BOLT, BRNS, JSPR, and QNTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BOLT Bolt Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	JSPR Jasper Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/28/2026	BOLT Bolt Biotherapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/28/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$4.70M	1.50	N/A	N/A	$6.56 per share	0.56
BRNS Barinthus Biotherapeutics	$14.97M	1.70	N/A	N/A	$1.40 per share	0.44
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.05 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$0.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$33.38M	-$16.44	N/A	N/A	N/A	-611.47%	-126.23%	-54.70%	11/11/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/5/2026 (Estimated)
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-884.17%	-143.83%	11/9/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$5.49	N/A	N/A	N/A	N/A	-582.23%	-184.20%	11/6/2026 (Estimated)

Latest BOLT, BRNS, JSPR, and QNTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A
8/13/2026	Q2 2026	QNTM Quantum Biopharma	-$0.4116	-$0.47	-$0.0584	-$0.47	N/A	N/A
8/11/2026	Q2 2026	BOLT Bolt Biotherapeutics	-$3.39	-$4.57	-$1.18	-$4.57	$0.50 million	$0.01 million
8/6/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	$0.36	9.84%	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	1.47	2.61	2.61
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
JSPR Jasper Therapeutics	N/A	1.48	2.26
QNTM Quantum Biopharma	N/A	1.20	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
BRNS Barinthus Biotherapeutics	25.20%
JSPR Jasper Therapeutics	79.85%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	9.40%
BRNS Barinthus Biotherapeutics	8.50%
JSPR Jasper Therapeutics	2.30%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	1.93 million	1.75 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
JSPR Jasper Therapeutics	20	28.00 million	27.35 million	Optionable
QNTM Quantum Biopharma	N/A	6.40 million	5.85 million	N/A

BOLT, BRNS, JSPR, and QNTM Headlines

Recent News About These Companies

Quantum Biopharma Provides Corporate Update

August 21 at 7:00 PM | globenewswire.com

Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20 at 6:50 PM | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20 at 1:50 PM | markets.businessinsider.com

Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | usatoday.com

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

August 14, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | markets.businessinsider.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial

August 11, 2026 | theglobeandmail.com

Quantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2

August 10, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

August 3, 2026 | markets.businessinsider.com

Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results

August 3, 2026 | finance.yahoo.com

Quantum BioPharma Announces Closing of Debt Settlement

July 29, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

July 29, 2026 | finance.yahoo.com

Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

July 22, 2026 | finance.yahoo.com

Quantum BioPharma Announces Intention to Settle Debt

July 20, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy

July 15, 2026 | finance.yahoo.com

Why Quantum BioPharma (QNTM) Is 'One to Watch'

July 10, 2026 | finance.yahoo.com

Quantum BioPharma Provides Corporate Update

July 7, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

July 2, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BOLT, BRNS, JSPR, and QNTM Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$3.66 +0.46 (+14.38%)

As of 08/21/2026 03:57 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.62 +0.01 (+1.54%)

As of 08/21/2026 02:30 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Jasper Therapeutics NASDAQ:JSPR

$0.72 +0.02 (+3.59%)

As of 08/21/2026 04:00 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Quantum Biopharma NASDAQ:QNTM

$3.44 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLT, BRNS, JSPR, and QNTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLT, BRNS, JSPR, and QNTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLT, BRNS, JSPR, and QNTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLT, BRNS, JSPR, and QNTM Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Barinthus Biotherapeutics NASDAQ:BRNS

Jasper Therapeutics NASDAQ:JSPR

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLT, BRNS, JSPR, and QNTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLT, BRNS, JSPR, and QNTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLT, BRNS, JSPR, and QNTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLT, BRNS, JSPR, and QNTM Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Barinthus Biotherapeutics NASDAQ:BRNS

Jasper Therapeutics NASDAQ:JSPR

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools